Ina V. Zurlo

Lecce, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.

On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.

Journal: Oncology research
Published: February 19, 2026

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Journal: Cancers
Published: October 02, 2025

Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data.

Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data.

Journal: Oncology
Published: August 29, 2025

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Journal: Cancers
Published: May 24, 2025

Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience.

Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience.

Journal: Therapeutic advances in medical oncology
Published: April 11, 2025

Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study).

Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study).

Journal: Cancer gene therapy
Published: April 03, 2025

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Journal: Current oncology (Toronto, Ont.)
Published: October 24, 2024

A Retrospective Analysis of Real-Life Management of Colorectal Cancer Lung-Limited Metastases Treated with Surgery: Outcomes and Prognostic Factors.

A Retrospective Analysis of Real-Life Management of Colorectal Cancer Lung-Limited Metastases Treated with Surgery: Outcomes and Prognostic Factors.

Journal: Journal of clinical medicine
Published: July 14, 2024

Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic.

Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic.

Journal: The oncologist
Published: June 26, 2024

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.

Journal: Targeted oncology
Published: March 06, 2024

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.

Journal: Cancers
Published: November 10, 2023

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.

Journal: Journal of clinical medicine
Published: November 04, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026